(Q44579323)

4 December 2017

REporting recommendations for tumor MARKer prognostic studies (REMARK). (English)

1 reference

4 December 2017

2

Douglas G Altman

1 reference

4 December 2017

Lisa M McShane

1

1 reference

4 December 2017

Willi Sauerbrei

3

1 reference

4 December 2017

Sheila E Taube

4

1 reference

4 December 2017

Massimo Gion

5

1 reference

4 December 2017

Gary M Clark

6

1 reference

4 December 2017

Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics

7

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

4 December 2017

Nature Reviews Urology

1 reference

4 December 2017

2

1 reference

4 December 2017

416-422

1 reference

4 December 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/ncponc0252

4 December 2017

0 references

cites work

The risk of determining risk with multivariable models

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

Statistical aspects of prognostic factor studies in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

Predicting the future: a critical appraisal of cancer prognosis studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

Review of survival analyses published in cancer journals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

Prognostic factors in non-small cell lung cancer: a decade of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

Methodological challenges in the evaluation of prognostic factors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

Systematic reviews of evaluations of prognostic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

Tumor markers as clinical cancer tests--are we there yet?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

Breast cancer prognostic factors: evaluation guidelines.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

The future of prognostic factors in outcome prediction for patients with cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

The American Joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

Prognostic variables in node-negative and node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

A systematic review of molecular and biological tumor markers in neuroblastoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

A guide for reviewing submitted manuscripts (and indications for the design of translational research studies on biomarkers)

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

Dangers of using "optimal" cutpoints in the evaluation of prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

Why do so many prognostic factors fail to pan out?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

Issues and barriers to development of clinically useful tumor markers: a development pathway proposal

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0252

7 January 2021

Identifiers

DOI

10.1038/NCPONC0252

1 reference

Dimensions Publication ID

4 December 2017

0 references

1 reference